PMID- 27417356
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160715
LR  - 20201001
IS  - 2227-9067 (Print)
IS  - 2227-9067 (Electronic)
IS  - 2227-9067 (Linking)
VI  - 2
IP  - 2
DP  - 2015 Apr 21
TI  - Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation 
      in Childhood.
PG  - 146-73
LID - 10.3390/children2020146 [doi]
AB  - Improving survival rates in children with malignancy have been achieved at the 
      cost of a high frequency of late adverse effects of treatment, especially in 
      intensively treated patients such as those undergoing haematopoietic stem cell 
      transplantation (HSCT), many of whom suffer the high burden of chronic toxicity. 
      Secondary malignant neoplasms (SMNs) are one of the most devastating late 
      effects, cause much morbidity and are the most frequent cause of late (yet still 
      premature) treatment-related mortality. They occur in up to 7% of HSCT recipients 
      by 20 years post-HSCT, and with no evidence yet of a plateau in incidence with 
      longer follow-up. This review describes the epidemiology, pathogenesis, clinical 
      features and risk factors of the three main categories of post-HSCT SMNs. A wide 
      range of solid SMNs has been described, usually occurring 10 years or more 
      post-HSCT, related most often to previous or conditioning radiotherapy. 
      Therapy-related acute myeloid leukaemia/myelodysplasia occurs earlier, typically 
      three to seven years post-HSCT, mainly in recipients of autologous transplant and 
      is related to previous alkylating agent or topoisomerase II inhibitor 
      chemotherapy. Post-transplant lymphoproliferative disorders occur early (usually 
      within two years) post-HSCT, usually presenting as Epstein-Barr virus-related B 
      cell non-Hodgkin lymphoma.
FAU - Bomken, Simon
AU  - Bomken S
AD  - Department of Paediatric and Adolescent Haematology/Oncology, Great North 
      Children's Hospital, Newcastle upon Tyne, NE1 4LP, UK. 
      s.n.bomken@newcastle.ac.uk.
FAU - Skinner, Roderick
AU  - Skinner R
AD  - Department of Paediatric and Adolescent Haematology/Oncology, Great North 
      Children's Hospital, Newcastle upon Tyne, NE1 4LP, UK. 
      Roderick.Skinner@ncl.ac.uk.
AD  - Children's Haemopoietic Stem Cell Transplant Unit, Great North Children's 
      Hospital, Newcastle upon Tyne, NE1 4LP, UK. Roderick.Skinner@ncl.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150421
PL  - Switzerland
TA  - Children (Basel)
JT  - Children (Basel, Switzerland)
JID - 101648936
PMC - PMC4928755
OTO - NOTNLM
OT  - children
OT  - haematopoietic stem cell transplant
OT  - post-transplant lymphoproliferative disorders
OT  - secondary malignant neoplasm
OT  - therapy-related acute myeloid leukaemia
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
PMCR- 2015/04/21
CRDT- 2016/07/16 06:00
PHST- 2014/12/10 00:00 [received]
PHST- 2015/04/03 00:00 [revised]
PHST- 2015/04/08 00:00 [accepted]
PHST- 2016/07/16 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PHST- 2015/04/21 00:00 [pmc-release]
AID - children2020146 [pii]
AID - children-02-00146 [pii]
AID - 10.3390/children2020146 [doi]
PST - epublish
SO  - Children (Basel). 2015 Apr 21;2(2):146-73. doi: 10.3390/children2020146.